Preliminary trial of specific targeting therapy against malignant glioma

This publication has 19 references indexed in Scilit:

• An in-vitro model for tumor immunotherapy with antibody heteroconjugates
  Immunology Today, 1988
• Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
  The Journal of Experimental Medicine, 1988
• Chapter 24 Serological and biochemical analysis of four antigens associated with small cell lung cancer
  Lung Cancer, 1988
• Increased Vascular Permeability in Organs Mediated by the Systemic Administration of Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 in Mice
  JNCI Journal of the National Cancer Institute, 1988
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
  Science, 1986
• Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies.
  The Journal of Experimental Medicine, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982